Factors affecting the particle size distribution and rheology of brinzolamide ophthalmic suspensions.
Acrylic Resins
/ chemistry
Carbonic Anhydrase Inhibitors
/ administration & dosage
Chemistry, Pharmaceutical
Drug Compounding
Drug Liberation
Excipients
/ chemistry
Mannitol
/ chemistry
Particle Size
Quality Control
Rheology
Sodium Chloride
/ chemistry
Sulfonamides
/ administration & dosage
Suspensions
Thiazines
/ administration & dosage
Viscosity
Brinzolamide
Milling
Particle size
Rheology
Suspension
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
30 Aug 2020
30 Aug 2020
Historique:
received:
02
03
2020
revised:
24
04
2020
accepted:
30
05
2020
pubmed:
20
6
2020
medline:
4
3
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
Drug particle size distribution (PSD) and dispersion viscosity are two critical quality attributes that govern the performance of topical ophthalmic suspensions, such as suspension physical stability, ocular retention, and drug release characteristics.. An in-depth knowledge of the effects of formulation and manufacturing process on these critical quality attributes may facilitate the product and process development, quality control, as well as support regulatory policy and approval. The current study has investigated the effect of formulation and process parameters on the quality attributes of brinzolamide ophthalmic suspensions. In the first step, three milling techniques (probe sonication, microfluidization, and media milling with a planetary centrifugal mixer) were evaluated for manufacturing of brinzolamide suspension. Out of the three techniques, the planetary centrifugal media milling yielded the narrowest PSD and thus was considered the most viable lab-scale technique for this purpose. In the next step, various process parameters of media milling were evaluated using a central-composite experimental design. The independent variables included bead size, agitating intensity, and process time while the PSD of drug particles (D
Identifiants
pubmed: 32553495
pii: S0378-5173(20)30479-8
doi: 10.1016/j.ijpharm.2020.119495
pii:
doi:
Substances chimiques
Acrylic Resins
0
Carbonic Anhydrase Inhibitors
0
Excipients
0
Sulfonamides
0
Suspensions
0
Thiazines
0
carbomer
0
Mannitol
3OWL53L36A
Sodium Chloride
451W47IQ8X
brinzolamide
9451Z89515
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119495Informations de copyright
Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.